Cost-Effectiveness of Antiretroviral Therapy and Isoniazid Prophylaxis to Reduce Tuberculosis and Death in People Living With HIV in Botswana
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
i

Superseded

This Document Has Been Replaced By:

i

Retired

This Document Has Been Retired

i

Up-to-date Information

This is the latest update:

Cost-Effectiveness of Antiretroviral Therapy and Isoniazid Prophylaxis to Reduce Tuberculosis and Death in People Living With HIV in Botswana
  • Published Date:

    Nov 01 2015

  • Source:
    J Acquir Immune Defic Syndr. 70(3):e84-e93
  • Language:
    English
Filetype[PDF-780.97 KB]


Details:
  • Alternative Title:
    J Acquir Immune Defic Syndr
  • Personal Author:
  • Description:
    Objective In Botswana, a 36-month course of isoniazid treatment of latent tuberculosis (TB) infection [isoniazid preventive therapy (IPT)] was superior to 6-month IPT in reducing TB and death in persons living with HIV (PLHIV), having positive tuberculin skin tests (TSTs) but not in those with negative TST. We examined the cost-effectiveness of IPT in Botswana, where antiretroviral therapy (ART) is widely available. Design Using a decision-analytic model, we determined the incremental cost-effectiveness of strategies for reducing TB and death in 10,000 PLHIV over 36 months. Methods IPT for 6 months and provision of ART if CD4+ lymphocyte count <250 cells per microliter (2011 Botswana policy) was compared with 6 alternative strategies that varied the use of IPT, TST, and ART for CD4+ count thresholds, including CD4+ <350 and <500 cells per microliter. Results Botswana policy, 2011 was dominated by most other strategies. IPT of 36 months for TST-positive PLHIV with ART for CD4+ <250 cells per microliter resulted in 120 fewer TB cases for an additional cost of $1612 per case averted and resulted in 80 fewer deaths for an additional $2418 per death averted compared with provision of 6-month IPT to TST-positive PLHIV who received ART for CD4+ <250 cells per microliter, the next most effective strategy. Alternative strategies offered lower incremental effectiveness at higher cost. These findings remained consistent in sensitivity analyses. Conclusions A strategy of treating PLHIV who have positive TST with 36-month IPT is more cost effective for reducing both TB and death compared with providing IPT without a TST, providing only 6-month IPT, or expanding ART eligibility without IPT.
  • Subject:
  • Pubmed ID:
    26258564
  • Pubmed Central ID:
    PMC5131632
  • Document Type:
    Journal Article
  • Funding:
    CC999999/Intramural CDC HHS/United States
  • Collection(s):
    CDC Public Access
  • Main Document Checksum:
  • File Type:
No Related Documents.

You May Also Like:

  1. Filetype[PDF - 29.50 KB]
    Personal Author:
    Lederer, Philip; Briggs, Melissa; Hassani, Ahmed Saadani; Date, Anand;
    Published Date:
    Jan 2015
    Source:
    Lancet Infect Dis. 15(1):14
    File Type:
    Filetype[PDF - 29.50 KB]
  2. Filetype[PDF - 454.90 KB]
    Personal Author:
    Samandari, Taraz; Agizew, Tefera B.; Nyirenda, Samba; Tedla, Zegabriel; Sibanda, Thabisa; Mosimaneotsile, Barudi; Motsamai, Oaitse I.; Shang, Nong; Rose, Charles E.; Shepherd, James;
    Published Date:
    Jan 28 2015
    Source:
    AIDS. 29(3):351-359
    Description:
    ObjectiveThirty-six months of isoniazid preventive therapy (36IPT) was superior to 6 months of IPT (6IPT) in preventing tuberculosis (TB) among HIV-infected adults in Botswana. We assessed the posttrial durability of this benefit.DesignA 36-month dou...
    File Type:
    Filetype[PDF - 454.90 KB]
  3. Filetype[PDF - 335.33 KB]
    Personal Author:
    Auerbach, Judith D.; Black, Roberta J.; Cheever, Laura.; Greenberg, Alan E.; Grohskopf, Lisa A.; Johnson, Michael; Onorato, Ida M.; Paxton, Lynn A.; Smith, Dawn K.; Struble, Kimberly A.; Veronese, Fulvia;
    Corporate Authors:
    National Center for HIV, STD, and TB Prevention (U.S.), Division of HIV/AIDS Prevention.. Centers for Disease Control and Prevention (U.S.).
    Published Date:
    January 21, 2005
    Series:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 54, no. RR-2
    Description:
    The most effective means of preventing human immunodeficiency virus (HIV) infection is preventing exposure. The provision of antiretroviral drugs to prevent HIV infection after unanticipated sexual or injection-drug--use exposure might be beneficial....
    Status:
    superseded
    File Type:
    Filetype[PDF - 335.33 KB]
  4. Filetype[PDF - 376.00 KB]
    Personal Author:
    Naidoo, Kogieleum; Grobler, Anneke C; Deghaye, Nicola; Reddy, Tarylee; Gengiah, Santhanalakshmi; Gray, Andrew; Karim, Salim Abdool;
    Published Date:
    Aug 15 2015
    Source:
    J Acquir Immune Defic Syndr. 69(5):576-584
    Description:
    ObjectiveInitiation of antiretroviral therapy (ART) during tuberculosis (TB) treatment improves survival in TB-HIV co-infected patients. In patients with CD4+ counts <50cells/mm3, there is a substantial clinical and survival benefit of early ART init...
    File Type:
    Filetype[PDF - 376.00 KB]
  5. Filetype[PDF - 770.00 KB]
    Personal Author:
    Knight, Gwenan M.; Dodd, Peter J.; Grant, Alison D.; Fielding, Katherine L.; Churchyard, Gavin J.; White, Richard G.;
    Published Date:
    April 07 2015
    Source:
    PLoS One. 2015; 10(4)
    Description:
    BackgroundSouth Africa has one of the highest per capita rates of tuberculosis (TB) incidence in the world. In 2012, the South African government produced a National Strategic Plan (NSP) to control the spread of TB with the ambitious aim of zero new ...
    File Type:
    Filetype[PDF - 770.00 KB]